Health Trials

Clinical trials

8

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine

Participants needed: 220
Trial details
Phase: Phase 3Age: 10-17Biological sex: AllType: InterventionalSponsor: Alkermes, Inc.Updated: Aug 14, 2026Locations: 47
Eligibility criteria

Subjects aged 13 to 17 years with schizophrenia or aged 10 to 17 years with bipo... [+4]

Subject presents with a major depressive episode(bipolar I disorder) or other ne... [+11]

Read more
Status: Recruiting

A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)

The purpose of this study is to measure safety and the improvement in symptoms in subjects with ADHD when taking ALKS 7290 tablets compared with placebo tablets.

Participants needed: 312
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Alkermes, Inc.Updated: Aug 10, 2026Locations: 2
Eligibility criteria

Meets the Diagnostic and Statistical Manual of Mental Disorders -5 criteria for... [+4]

Has a known history of intellectual developmental disorder or cognitive impairme... [+4]

Read more
Status: Recruiting

A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)

The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets.

Participants needed: 150
Trial details
Phase: Phase 3Age: 18-70Biological sex: AllType: InterventionalSponsor: Alkermes, Inc.Updated: Aug 7, 2026Locations: 14
Eligibility criteria

Meets the diagnostic criteria of NT1 according to ICSD-3-TR guidelines, confirme...

Has another comorbid sleep disorder or condition that may influence the sleep-wa... [+3]

Read more
Status: Recruiting

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

The purpose of this study is to measure decreases in daytime sleepiness, and disease symptoms in participants with Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets compared with placebo tablets.

Participants needed: 176
Trial details
Phase: Phase 3Age: 18-70Biological sex: AllType: InterventionalSponsor: Alkermes, Inc.Updated: Aug 7, 2026Locations: 28
Eligibility criteria

Is willing and able, in the opinion of the Investigator, to understand and compl... [+1]

Has another comorbid sleep disorder or condition that may influence the sleep-wa... [+3]

Read more
Status: Recruiting

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets.

Participants needed: 150
Trial details
Phase: Phase 3Age: 18-70Biological sex: AllType: InterventionalSponsor: Alkermes, Inc.Updated: Aug 7, 2026Locations: 29
Eligibility criteria

Meets the diagnostic criteria of NT1 according to ICSD-3-TR guidelines, confirme...

Has another comorbid sleep disorder or condition that may influence the sleep-wa... [+3]

Read more
Status: Recruiting

A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), or Idiopathic Hypersomnia (IH) when taking ALKS 2680 tablets.

Participants needed: 256
Trial details
Phase: Phase 2, Phase 3Age: 18-70Biological sex: AllType: InterventionalSponsor: Alkermes, Inc.Updated: Aug 7, 2026Locations: 49
Eligibility criteria

Was eligible for and has completed end of treatment visit of ALKS 2680 eligible... [+1]

Developed a new clinically significant health condition, ECG or laboratory abnor... [+2]

Read more
Status: Available

An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipolar I Disorder (ALKS 3831-315)

To provide continued access to OLZ/SAM for pediatric participants with schizophrenia or bipolar I disorder who have completed participation in the ALKS 3831-A313 long-term safety extension study.

Trial details
Age: 10-17Biological sex: AllType: Expanded AccessSponsor: Alkermes, Inc.Updated: Aug 4, 2026Locations: 1
Eligibility criteria

The Participant has completed 52-weeks on the ALKS 3831-A313 clinical study. [+5]

The participant is eligible for commercial OLZ/SAM (LYBALVI®) through standard c... [+6]

Read more
Status: Recruiting

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia

The purpose of this study is to measure the safety and decrease in daytime sleepiness in subjects with Idiopathic Hypersomnia when taking ALKS 2680 tablets compared with placebo tablets

Participants needed: 126
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Alkermes, Inc.Updated: Jun 24, 2026Locations: 50
Eligibility criteria

Is willing and able, in the opinion of the Investigator, to understand and compl... [+1]

Has another comorbid sleep disorder or condition that may influence the sleep-wa... [+3]

Read more